The U.S. National Institutes of Health (the University of Pennsylvania) has approved a proposal by NIH to use gene-editing technology, CRISPR-Cas9 in a clinical trial to boost existing cancer therapies. This ground-breaking biomedical treatment will be used in 'first in human' clinical trials, and researchers hope the technique will improve cancer treatments and remove some of the patient's vulnerabilities to diseases, which can often cause a relapse. This first Phase 1 trial will seek to show CRISPR is safe for use in humans. Patients will be recruited from Texas and California.
The U.S. National Institutes of Health (NIH) has approved a proposal by the University of Pennsylvania to use gene-editing technology, CRISPR-Cas9 in a clinical trial to boost existing cancer therapies. This ground-breaking biomedical treatment will be used in 'first in human' clinical trials, and researchers hope the technique will improve cancer treatments and remove some of the patient's vulnerabilities to diseases, which can often cause a relapse. This first Phase 1 trial will seek to show CRISPR is safe for use in humans. Patients will be recruited from Texas and California.